Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Profit After Tax: 2023-2024

Historic Profit After Tax for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$42.3 million.

  • Contineum Therapeutics' Profit After Tax fell 87.93% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 286.29%. This contributed to the annual value of -$42.3 million for FY2024, which is 286.18% down from last year.
  • As of FY2024, Contineum Therapeutics' Profit After Tax stood at -$42.3 million, which was down 286.18% from $22.7 million recorded in FY2023.
  • Contineum Therapeutics' Profit After Tax's 5-year high stood at $22.7 million during FY2023, with a 5-year trough of -$42.3 million in FY2024.
  • Over the past 2 years, Contineum Therapeutics' median Profit After Tax value was -$9.8 million (recorded in 2023), while the average stood at -$9.8 million.
  • Data for Contineum Therapeutics' Profit After Tax shows a maximum YoY tumbled of 286.18% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Profit After Tax (Yearly) stood at $22.7 million in 2023, then slumped by 286.18% to -$42.3 million in 2024.